I think any updates on the information arm as well as finally seeing the data from the EAP trial (compassionate use) trial will be extremely helpful. But I don’t think this data can be used as an external control, if that’s what you were meaning, because all of these patients received DCVax. They also were comprised of primarily rapid progressors and original pseudoprogression (from chemo rad) patients, while the main arm would have been the more in-between group.
Market Data 
Markets 
AI
